Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.

NCT Number	NCT06731413
Lead Sponsor	Virginia Commonwealth University
Conditions	Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Enrollment	40 participants
Start Date	2025-02-11
Primary Completion	2030-07-30 (estimated)
Study Completion	2033-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-02